Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Bone Marrow Transplant

Non-myeloablative Transplants for CLL and SLL (FH-1840)
Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status Conditions Phase Study ID
Recruiting Leukemia
Lymphoma
Phase II FH 1840
NCT00104858
Summary

The purpose of this study is to determine whether or not a certain type of stem-cell transplant (non-myeloablative), is effective in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Non-myeloablative stem-cell transplants use lower doses of chemotherapy and radiation than conventional stem-cell transplants.

Study participants will receive the drug fludarabine together with radiation therapy before undergoing donor stem-cell transplant. Participants will also receive the drug Rituximab just before and after the transplant. This study is for patients whose disease did not respond to previous treatment with fludarabine alone or have poor-risk chromosomes.

Treatment will last about 3 1/2 months, but could be longer. We plan for most of the treatment to occur at the Seattle Cancer Care Alliance outpatient clinic. If hospitalization is needed, the participant will be admitted to the University of Washington Medical Center.


Investigator
Mohamed Sorror, MD, MSc
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)

1. Diagnosis of one of the following: 

  • Chronic lymphocytic leukemia (CLL)
  • Small lymphocytic lymphoma (SLL)
  • CLL that progresses to prolymphocytic leukemia (PLL) 
  • T-cell CLL or PLL

2. Disease that did not adequately respond (according to study guidelines) to prior therapy that included fludarabine (or similar drug), or disease returned after therapy with fludarabine. Also, patients with (deletion 17p) chromosomal abnormaility will be eligible for enrollment.

3. Suitable HLA-matched related or unrelated donor.

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

1. HIV-positive or other active infection

2. Active diagnosis of central nervous system involvement with CLL

3. Pregnancy or breastfeeding

4. Severe heart, liver, kidney or lung disorders

Other exclusion criteria may apply.

Last Updated
November 07, 2012
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.